{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:44:32Z","timestamp":1790959472698,"version":"4.1.0"},"reference-count":32,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Objective: To characterize the frequency, timing, patterns of first distant metastasis, and post-metastatic survival in uterine sarcoma using population-based registry data. Methods: This study included all patients diagnosed with uterine sarcoma between 2000 and October 2025 in the regional cancer registry of Saxony-Anhalt, Germany. Patients with carcinosarcoma were excluded. Metastatic disease was classified as primary (present at diagnosis or \u22643 months) or metachronous (&gt;3 months). Metastatic patterns were analyzed based on the first metastatic presentation only. Overall survival (OS), recurrence-free survival (RFS), and post-metastatic OS were estimated using Kaplan\u2013Meier methods. RFS was defined as the interval from confirmed tumor-free status after primary therapy to first recurrence or death, and was restricted to patients who achieved tumor-free status (n = 114). Multivariable Cox regression analyses for OS and RFS were performed with administrative censoring at 5 years. Results: A total of 155 patients with uterine sarcoma were included. During follow-up, 54 patients (34.8%) were diagnosed with metastatic disease, of whom 30 (55.6%) presented with primary metastatic disease. Lung was the most frequent site of first metastasis, followed by bone, peritoneum, and liver; 43.4% of metastatic patients had multiple synchronous metastatic sites at first presentation. Median time to first metastasis was short, with several metastatic sites showing median values of zero months, reflecting the high proportion of primary metastatic disease. Median post-metastatic OS was 12 months. Advanced FIGO (F\u00e9d\u00e9ration Internationale de Gyn\u00e9cologie et d\u2019Obst\u00e9trique) stage and failure to achieve tumor-free status after primary therapy were independently associated with worse OS, whereas histologic subtype was not. Conclusions: In this population-based cohort, metastatic disease occurred in more than one-third of patients with uterine sarcoma and was frequently present at diagnosis. Lung metastases predominated as the first site of distant spread, and post-metastatic survival was poor. These findings underscore the importance of comprehensive staging at diagnosis and highlight the aggressive metastatic behavior of uterine sarcoma in real-world practice.<\/jats:p>","DOI":"10.3390\/cancers18091415","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:34:42Z","timestamp":1777458882000},"page":"1415","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mapping Metastatic Spread in Uterine Sarcoma: A Population-Based Analysis of First Metastatic Patterns and Outcomes"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5286-7735","authenticated-orcid":false,"given":"Paolo","family":"Gennari","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Otto-Von-Guericke University, Gerhard-Hauptmann-Str. 35, 39108 Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atanas","family":"Ignatov","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Otto-Von-Guericke University, Gerhard-Hauptmann-Str. 35, 39108 Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ijgo.12612","article-title":"Cancer of the corpus uteri","volume":"143","author":"Amant","year":"2018","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ygyno.2009.09.023","article-title":"Uterine sarcomas: A review","volume":"116","author":"Prat","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.ejca.2012.09.011","article-title":"Descriptive epidemiology of sarcomas in Europe: Report from the RARECARE project","volume":"49","author":"Stiller","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JCO.2017.75.9845","article-title":"Soft tissue and uterine leiomyosarcoma","volume":"36","author":"George","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/cncr.23245","article-title":"Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: Emphasis on impact of lymphadenectomy and oophorectomy","volume":"112","author":"Kapp","year":"2008","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/ijgc-2022-004204","article-title":"Prognostic factors in patients with uterine sarcoma: The SARCUT study","volume":"33","author":"Zapardiel","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"04155","DOI":"10.7189\/jogh.14.04155","article-title":"Global burden of gynaecological cancers in 2022 and projections to 2050","volume":"14","author":"Zhu","year":"2024","journal-title":"J. Glob. Health"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/ijgo.12613","article-title":"Uterine sarcomas","volume":"143","author":"Mbatani","year":"2018","journal-title":"Int. J. Gynecol. Obstet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijgo.2008.12.008","article-title":"FIGO staging for uterine sarcomas","volume":"104","author":"Prat","year":"2009","journal-title":"Int. J. Gynecol. Obstet."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ygyno.2014.10.022","article-title":"Uterine adenosarcoma: An analysis on management, outcomes, and risk factors for recurrence","volume":"135","author":"Carroll","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ygyno.2017.02.012","article-title":"Prognosis and treatment of uterine leiomyosarcoma: A National Cancer Database study","volume":"145","author":"Seagle","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Aggarwal, A., Ferrari, F., Zouridis, A., Kehoe, S., Pratap, S., Gozzini, E., and Soleymani Majd, H. (2024). Survival Trends for Uterine Sarcomas from a Tertiary Center: The Oxford Experience. Diseases, 12.","DOI":"10.3390\/diseases12090200"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/cncr.26333","article-title":"A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma","volume":"118","author":"Zivanovic","year":"2012","journal-title":"Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1097\/IGC.0000000000000720","article-title":"Uterine Sarcoma: Analysis of 13,089 Cases Based on Surveillance, Epidemiology, and End Results Database","volume":"26","author":"Hosh","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_16","unstructured":"National Comprehensive Cancer Network (2024). NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms, National Comprehensive Cancer Network. Version 1.2024."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3802\/jgo.2014.25.4.306","article-title":"Metastatic pattern of uterine leiomyosarcoma","volume":"25","author":"Tirumani","year":"2014","journal-title":"J. Gynecol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/1097-0142(19890301)63:5<935::AID-CNCR2820630525>3.0.CO;2-9","article-title":"Patterns of metastasis in uterine sarcoma: An autopsy study","volume":"63","author":"Rose","year":"1989","journal-title":"Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0090-8258(03)00478-5","article-title":"Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus","volume":"91","author":"Leitao","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1136\/ijgc-2024-005823","article-title":"ESGO\/EURACAN\/GCIG guidelines for the management of patients with uterine sarcomas","volume":"34","author":"Casali","year":"2024","journal-title":"Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc."},{"key":"ref_21","first-page":"101153","article-title":"Treatment patterns and outcomes for primary uterine leiomyosarcoma presenting with synchronous isolated lung metastases: A National Cancer Database study of primary resection and metastasectomy","volume":"46","author":"Istl","year":"2024","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Ricotta, G., Russo, S.A., Fagotti, A., Martinez, A., Gauroy, E., Del, M., Thibaud, V., Guillaume, B., and Ferron, G. (2025). Endometrial Stromal Sarcoma: An Update. Cancers, 17.","DOI":"10.3390\/cancers17111893"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.pathol.2017.11.086","article-title":"Endometrial stromal sarcomas and related neoplasms: New developments and diagnostic considerations","volume":"50","author":"Hoang","year":"2018","journal-title":"Pathology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/s41379-022-01011-z","article-title":"A novel morphology-based risk stratification model for stage I uterine leiomyosarcoma: An analysis of 203 cases","volume":"35","author":"Chapel","year":"2022","journal-title":"Mod. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.22514\/ejgo.2024.071","article-title":"Diagnostics and treatment of uterine sarcomas: Challenges of a low-volume tertiary centre","volume":"45","author":"Cokan","year":"2024","journal-title":"Eur. J. Gynaecol. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1055\/s-0035-1545684","article-title":"Surgical Methods for the Treatment of Uterine Fibroids\u2014Risk of Uterine Sarcoma and Problems of Morcellation: Position Paper of the DGGG","volume":"75","author":"Beckmann","year":"2015","journal-title":"Geburtshilfe Frauenheilkd."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e211658","DOI":"10.1148\/radiol.211658","article-title":"MRI Evaluation of Uterine Masses for Risk of Leiomyosarcoma: A Consensus Statement","volume":"306","author":"Hindman","year":"2023","journal-title":"Radiology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/S1470-2045(17)30445-X","article-title":"Burden and centralised treatment in Europe of rare tumours: Results of RARECAREnet\u2014A population-based study","volume":"18","author":"Gatta","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jtcvs.2017.02.061","article-title":"Pulmonary metastasectomy with therapeutic intent for soft-tissue sarcoma","volume":"154","author":"Chudgar","year":"2017","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Delisle, M., Alshamsan, B., Nagaratnam, K., Smith, D., Wang, Y., and Srikanthan, A. (2022). Metastasectomy in Leiomyosarcoma: A Systematic Review and Pooled Survival Analysis. Cancers, 14.","DOI":"10.3390\/cancers14133055"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1200\/JCO.18.00454","article-title":"Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology\/Gynecologic Oncology Group Study","volume":"36","author":"Hensley","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ygyno.2011.04.021","article-title":"The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma","volume":"122","author":"Park","year":"2011","journal-title":"Gynecol. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/9\/1415\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:49:38Z","timestamp":1777459778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/9\/1415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":32,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["cancers18091415"],"URL":"https:\/\/doi.org\/10.3390\/cancers18091415","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]}}}